Stem Cells and Biological Approaches to Treatment of Wrist Problems

Alphonsus K. S. Chong, MD^{1,2} Min He, PhD^{1,2}

¹Department of Hand and Reconstructive Microsurgery, National University Hospital, Singapore

²Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Address for correspondence Alphonsus K. S. Chong, 1E Kent Ridge Road, NUHS Tower Block, Level 11, Singapore 119228 (e-mail: doscksa@nus.edu.sg).

J Wrist Surg 2013;2:315–318.

Abstract

Keywords

- wrist
- stem cells
- experimental
- therapeutics

Stem cells are being intensively studied for their potential applications in clinical medicine. Mesenchymal stem cells (MSCs) are an important subset of stem cells which are attractive for application in musculoskeletal disorders. In this article, we review the characteristics of these MSCs that are relevant to clinical practice but that are still largely experimental in nature.

Human embryonic stem cells (ESCs) derived from blastocysts are pluripotent stem cells that can differentiate into any cell derivative of the ectoderm, endoderm, and mesoderm. Moreover, ESCs have a nearly unlimited replicating capacity. However, their application in transplantation and tissue engineering is greatly hindered by the risk of tumor formation and political and ethical concerns.¹

A group of plastic-adherent, fibroblast-like cells (► **Fig. 1**) were first derived from bone marrow in tissue culture plates in the 1980s.² These cells had the characteristics of stem cells including self-renewal and differentiation potential. These cells were given many names, including mesenchymal stem cells (MSCs), mesenchymal progenitors, and multipotent stromal cells. The therapeutic potential of MSCs has generated an enormous interest in a wide range of biomedical disciplines. The Mesenchymal and Tissue Stem Cell Committee of International Society for Cellular Therapy proposed a minimal set of standard criteria when using these cells for research to provide a standard definition of human multipotent mesenchymal stromal cells. This definition includes the following: (1) The MSC must be plastic-adherent when maintained in standard culture conditions. (2) The MSC must express specific surface antigen markers CD105, CD73 and CD90 and must not express CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR surface molecules. (3) The MSC must have the capacity to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro.³ The surface pheno-

type, in combination with the other functional criteria, best identifies MSC with the current state of knowledge.³

Despite this definition of MSCs, it is important to understand that MSCs are a heterogeneous population of cells and lack a unique marker.⁴ Besides differentiating into specific lineages of mesoderm origin such as osteocytes, chondrocytes, tenocytes, and muscle cells, MSCs can also transdifferentiate into cell types of the other germ layers such as neurons, hepatocytes, cardiomyocytes, pancreatic, and renal cell types under very defined conditions.⁵

Isolation and Expansion of MSCs

MSCs from bone marrow aspirate can be isolated by a variety of methods. Two commonly used techniques include the direct plating method and the density centrifugation method. Both methods produce very similar populations of MSCs. In the direct plating method, the bone marrow sample is diluted with an MSC growth medium and cultured without any disturbance at 37°C for 4–5 days. The medium is changed every 3–4 days, and contaminating red cells and other non-replicating and nonattaching cells are isolated and rinsed away. In the density centrifugation method, an initial isolation of mononuclear cells using a Ficoll density solution is performed, and then mononuclear cells are collected and cultured in an MSC growth medium. In some studies, the MSCs are further purified based on their expression of

Fig. 1 The fibroblast-like appearance of bone marrow-derived mesenchymal stem cells after in vitro expansion.

primitive MSC markers.⁵ Experiments on rat MSCs have shown that direct plating density may be not critical for maintaining a multipotent MSC population. However, culture time may affect cell characteristics, including cell morphology and differentiation potential, suggesting that cell expansion should be limited.⁶

MSC-like cells have been found in human fetal blood and umbilical cord blood.^{7,8} In adults, besides the bone marrow, MSCs can be isolated from multiple tissue sites including adipose tissue, synovium, periosteum, and muscle.^{9–11}

MSCs in Articular Cartilage

Articular cartilage, which consists mostly hyaline cartilage, has a limited capacity to regenerate or self-repair. Osteoarthritis often affects joints that are subjected to high-loading conditions, which may lead to a dramatic loss of articular cartilage. Autologous chondrocyte implantation (ACI) is currently the most common reconstructive technique for replacing articular cartilage.¹² ACI includes the following steps: (1) Harvest a small piece of articular cartilage from the patient. (2) Subsequently, this biopsy is enzymatically treated to isolate the chondrocytes. The chondrocytes are expanded in vitro. (3) The patient then undergoes a second operation, in which the expanded chondrocytes are applied on the damaged area of cartilage. The implanted autologous chondrocytes are presumed to regenerate the damaged cartilage. Biopsy specimens from patients who underwent autologous chondrocyte transplantation tissue after 2 years showed evidence of fibrous tissue and fibrocartilage formation instead of typical hyaline cartilage. Viable chondrocytes have been seen in the biopsy samples.^{13,14} The expansion of chondrocytes in vitro for ACI induces the dedifferentiation of chondrocytes, characterized by the loss of expression of type II collagen and aggrecan in favor of fibrotic type I and III collagens.¹⁵

In an attempt to improve the outcomes, the use of stem cells to regenerate cartilage have been investigated. It is well established that MSCs can manipulated in vitro to undergo chondrogenic or osteogenic differentiation. Comparative

analysis has shown that bone marrow–derived MSCs have a slightly superior chondrogenic potential when compared with adipose tissue–derived MSCs.¹⁶ Synovium and bone marrow MSCs had a greater in vivo chondrogenic potential than adipose and muscle MSCs, but synovium MSCs had the advantage of a greater proliferation potential.¹⁷ Saw et al have found that arthroscopic subchondral drilling, followed by postoperative intraarticular injections of autologous peripheral blood stem cells in combination with hyaluronic acid, improved the quality of articular cartilage repair on knees, as shown by histologic and magnetic resonance imaging (MRI) evaluation.^{18,19}

Bone marrow–derived MSCs have been used in attempts to regenerate articular cartilage in vivo in humans. Kuroda et al treated a 20 × 30-mm full-thickness articular cartilage defect in the femoral condyle of a judo athlete with autologous bone marrow stromal cells.²⁰ Bone marrow was aspirated from the iliac crest of the patient 4 weeks before surgery, and mesenchymal stem cells were expanded in vitro before transplantation into a collagen gel. Gel-cell composite was covered with an autologous periosteal flap. The autologous periosteal patch was affixed to the surrounding rim of the normal cartilage with interrupted absorbable sutures. Seven months after surgery, arthroscopy revealed that the defect was covered with smooth tissues. Histologically, the defect was filled with hyaline-like cartilage tissue that stained positively with both safranin-O and toluidine blue. Immunohistochemistry for type II collagen revealed a positive staining. One year after surgery, the clinical symptoms had improved significantly. Gianinni et al used a one-step repair technique to repair talar osteochondral lesions (chronic type II <1.5 cm² in area, <5 mm deep) in 48 patients, using a malleable paste that was composed of collagen, bone marrow concentrate, and platelet-rich fibrin.²¹ Two years after surgery, functional scores using the American Orthopaedic Foot and Ankle Society (AOFAS) scores were improved. However, histologic and immunohistologic results showed the presence of new cartilaginous tissues with various degrees of tissue remodeling toward hyaline cartilage. Haleem et al used MSCs transplanted on a scaffold of platelet-rich fibrin glue in the treatment of articular cartilage defects (defect size: 3 to 12 cm²) in the knees of five patients. Symptoms and knee scores (Lysholm and Revised Hospital for Special Surgery Knee scores) were improved in all patients.²² Controlling MSCs' differentiation to regenerate hyaline cartilage instead of fibrocartilage in vivo remains a major challenge.

MSCs in Bone Repair

Bone has a much superior regeneration capacity compared with cartilage. This difference is probably due to a large number of cells involved in the bone innate repair response, including osteoclasts, osteoblasts, periosteum, and bone marrow–derived stem cells.²³ The extensive vascularity in bone also provides sufficient nutrition and growth factors during the self-repair process.²³ The limits of bone regeneration are reached when there is significant bone loss or in situations where vascularity of the bone is tenuous, for example in the

scaphoid. In those situations, there is a clinical need to enhance bone repair and regeneration. MSCs provide an osteoblast supply during adulthood; therefore they are the cells of particular interest in research for bone regeneration.

Stem cell therapy has achieved fracture healing in several different animal models. Kadiyala et al implanted human bone marrow–derived MSCs with a ceramic carrier into critical-sized segmental defects in the femurs of adult athymic rats.²⁴ Histological evaluation demonstrated increasing bone formation by MSC implantation through 12 weeks. Femurs implanted with MSC-loaded ceramics were significantly stronger biomechanically than those that received cell-free ceramics. Petite et al implanted MSCs with a coral scaffold in large segmental bone defects in sheep.²⁵ Clinical union never occurred when the defects were left empty or filled with the coral scaffold alone (seven operated limbs in each group). In contrast, clinical union was obtained in three out of seven operated limbs when the defects were filled with the tissue-engineered bone. Lee et al treated a case of canine nonunion fracture with autologous adipose-derived MSCs seeded on a hydroxyapatite/chitosan composite scaffold.²⁶ Three months after surgery, the nonunion successfully healed with no complications.

Percutaneous injection of autologous bone marrow has been used to promote bone healing in humans in several clinical studies since the 1990s.^{27–29} In these studies, bone union was obtained in ~75–90% patients. However, no statistical comparisons were made. Bone marrow serves as a promptly renewable and reliable source of osteogenic stem cells, and its efficacy appears to be related to the number of progenitors in the graft.²⁸ Administration of MSCs has also shown promising results in human. Successful healing of a 9-year old tibial nonunion resistant to six previous surgical procedures was achieved by combination of in vitro–expanded bone marrow–derived MSCs and calcium sulfate pellets two months after implantation.³⁰ The clinical use of enriched bone marrow MSCs combined with porous β -tricalcium phosphate had a 95.1% union rate in spinal fusion; however, in that study no controls were used.³¹ Stem cell implantation, or stem cells coupled with gene therapy, may have the potential to treat nonunion of the scaphoid³²; however, direct evidence in animal models or in clinical studies is not available yet to the best of our knowledge.

MSCs in Wrist Disorders

Arthrosis is characterized by degeneration of the articular cartilage and, ultimately, joint destruction. In a donkey model of osteoarthritis induced by amphotericin-B, MSCs labeled with green fluorescent protein were detected in all examined articular cartilages, indicating successful homing after intra-articular injection of stem cells.³³ MSCs only partially delayed cartilage deterioration in this model.³³ Similarly in a horse model of osteoarthritis induced arthroscopically, MSCs did not show a significant therapeutic effect. Further study is required to validate the effect of stem cell treatment in arthrosis.³⁴

Kienböck disease, or avascular necrosis of the lunate, was first described in 1910. Osteonecrosis of the lunate will lead to

wrist pain and loss of function. In the early stage, this disorder has been treated by a joint-leveling procedure in an attempt to prevent collapse of the lunate. In the late stages, when there is fragmentation and lunate collapse, salvage procedures are performed such as a proximal row carpectomy or lunate excision and partial wrist fusion. Stem cell–based tissue engineering strategies might provide an alternative treatment method. In a rabbit lunate excision model, implantation of bone marrow–derived MSCs with a gelatin and hyaluronan scaffold maintained carpal height by 6 weeks, compared with the control group.³⁵ Abundant bone formation as well as evidence of neovascularization was observed by 12 weeks.³⁵ Implantation of MSCs preincubated in a chondrogenic medium with a scaffold also promoted bone and cartilage formation and stimulated vascularization in a rabbit model after 12 weeks.³⁶ Similarly, insertion of hybrid tendon rolls with a core of collagen–ceramic composite seeded with MSCs induced bone formation in the central part and cartilage formation at the peripheral part of the lunate.³⁷ In other studies, bone necrosis in rabbits was created by freezing and thawing the bone with liquid nitrogen. Drilling and bone marrow injection into the necrotic lunate accelerated bone formation and remodeling compared with the control group.³⁸ In a dog model, liquid nitrogen–treated scapholunate showed no regeneration of bone tissue, demonstrating severe collapse and deformity as observed in human Kienböck disease.³⁹ However, liquid nitrogen–treated scapholunate that were subsequently seeded with MSCs showed no collapse and deformity, and the cavity was completely filled with normal cancellous bone within 4 weeks.³⁹

The limitations of these studies in animal models include the following: (1) Biomechanical features of regenerated tissues are unknown. It is still not clear whether they can bear the pressure from surrounding bones during active movement in human. (2) The follow-up time is relatively short. The long-term effect of MSCs has not been investigated. (3) The studies use an acute model of chronic phenomena.⁴⁰ It is unclear whether the findings will be translated to actual clinical situations. Future clinical studies are crucial for gaining convincing evidence of therapeutic potential of MSCs in wrist disorders.

Conflict of Interest

None

References

- 1 Mertes H, Pennings G. Cross-border research on human embryonic stem cells: legal and ethical considerations. *Stem Cell Rev* 2009; 5(1):10–17
- 2 Friedenstien AJ, Latzinik NW, Grosheva AG, Gorskaya UF. Marrow microenvironment transfer by heterotopic transplantation of freshly isolated and cultured cells in porous sponges. *Exp Hematol* 1982;10(2):217–227
- 3 Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006;8(4):315–317

- 4 Steinert AF, Rackwitz L, Gilbert F, Nöth U, Tuan RS. Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. *Stem Cells Transl Med* 2012;1(3):237–247
- 5 Gregory CA, Prockop DJ, Spees JL. Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation. *Exp Cell Res* 2005;306(2):330–335
- 6 Neuhuber B, Swanger SA, Howard L, Mackay A, Fischer I. Effects of plating density and culture time on bone marrow stromal cell characteristics. *Exp Hematol* 2008;36(9):1176–1185
- 7 Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. *Blood* 2001;98(8):2396–2402
- 8 Hutson EL, Boyer S, Genever PG. Rapid isolation, expansion, and differentiation of osteoprogenitors from full-term umbilical cord blood. *Tissue Eng* 2005;11(9-10):1407–1420
- 9 Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 2001;7(2):211–228
- 10 Shirasawa S, Sekiya I, Sakaguchi Y, Yagishita K, Ichinose S, Muneta T. In vitro chondrogenesis of human synovium-derived mesenchymal stem cells: optimal condition and comparison with bone marrow-derived cells. *J Cell Biochem* 2006;97(1):84–97
- 11 Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. *Cell Tissue Res* 2007;327(3):449–462
- 12 Behrens P, Bosch U, Bruns J, et al; German Society for Traumatology; German Society for Orthopedic Surgery. Indications and implementation of recommendations of the working group “Tissue Regeneration and Tissue Substitutes” for autologous chondrocyte transplantation (ACT) [in German]. *Z Orthop Ihre Grenzgeb* 2004;142(5):529–539
- 13 Grigolo B, Roseti L, De Franceschi L, et al. Molecular and immunohistological characterization of human cartilage two years following autologous cell transplantation. *J Bone Joint Surg Am* 2005;87(1):46–57
- 14 Horas U, Pelinkovic D, Herr G, Aigner T, Schnettler R. Autologous chondrocyte implantation and osteochondral cylinder transplantation in cartilage repair of the knee joint. A prospective, comparative trial. *J Bone Joint Surg Am* 2003;85-A(2):185–192
- 15 Demoor M, Maneix L, Ollitrault D, et al. Deciphering chondrocyte behaviour in matrix-induced autologous chondrocyte implantation to undergo accurate cartilage repair with hyaline matrix. *Pathol Biol (Paris)* 2012;60(3):199–207
- 16 Danisovic L, Varga I, Polák S, et al. Comparison of in vitro chondrogenic potential of human mesenchymal stem cells derived from bone marrow and adipose tissue. *Gen Physiol Biophys* 2009;28(1):56–62
- 17 Koga H, Muneta T, Nagase T, et al. Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit. *Cell Tissue Res* 2008;333(2):207–215
- 18 Saw KY, Anz A, Siew-Yoke Jee C, et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. *Arthroscopy* 2013;29(4):684–694
- 19 Saw KY, Anz A, Merican S, et al. Articular cartilage regeneration with autologous peripheral blood progenitor cells and hyaluronic acid after arthroscopic subchondral drilling: a report of 5 cases with histology. *Arthroscopy* 2011;27(4):493–506
- 20 Kuroda R, Ishida K, Matsumoto T, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. *Osteoarthritis Cartilage* 2007;15(2):226–231
- 21 Giannini S, Buda R, Vannini F, Cavallo M, Grigolo B. One-step bone marrow-derived cell transplantation in talar osteochondral lesions. *Clin Orthop Relat Res* 2009;467(12):3307–3320
- 22 Haleem AM, Singergy AA, Sabry D, et al. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. *Cartilage* 2010;1(4):253–261
- 23 Huey DJ, Hu JC, Athanasiou KA. Unlike bone, cartilage regeneration remains elusive. *Science* 2012;338(6109):917–921
- 24 Bruder SP, Kurth AA, Shea M, Hayes WC, Jaiswal N, Kadiyala S. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. *J Orthop Res* 1998;16(2):155–162
- 25 Petite H, Viateau V, Bensaid W, et al. Tissue-engineered bone regeneration. *Nat Biotechnol* 2000;18(9):959–963
- 26 Lee HB, Chung YS, Heo SY, Kim NS. Augmentation of bone healing of nonunion fracture using stem cell based tissue engineering in a dog: a case report. *Veterinární Medicína* 2009;54(4):198–203
- 27 Connolly JF, Guse R, Tiedeman J, Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial nonunions. *Clin Orthop Relat Res* 1991;(266):259–270
- 28 Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. *J Bone Joint Surg Am* 2005;87(7):1430–1437
- 29 Goel A, Sangwan SS, Siwach RC, Ali AM. Percutaneous bone marrow grafting for the treatment of tibial non-union. *Injury* 2005;36(1):203–206
- 30 Bajada S, Harrison PE, Ashton BA, Cassar-Pullicino VN, Ashammakhi N, Richardson JB. Successful treatment of refractory tibial nonunion using calcium sulphate and bone marrow stromal cell implantation. *J Bone Joint Surg Br* 2007;89(10):1382–1386
- 31 Gan Y, Dai K, Zhang P, Tang T, Zhu Z, Lu J. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. *Biomaterials* 2008;29(29):3973–3982
- 32 Young BH, Peng H, Huard J. Muscle-based gene therapy and tissue engineering to improve bone healing. *Clin Orthop Relat Res* 2002(403, Suppl):S243–S251
- 33 Mokbel AN, El Tookhy OS, Shamaa AA, Rashed LA, Sabry D, El Sayed AM. Homing and reparative effect of intra-articular injection of autologous mesenchymal stem cells in osteoarthritic animal model. *BMC Musculoskelet Disord* 2011;12:259
- 34 Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis. *J Orthop Res* 2009;27(12):1675–1680
- 35 Huang JL, Durbhakula MM, Angele P, Johnstone B, Yoo JU. Lunate arthroplasty with autologous mesenchymal stem cells in a rabbit model. *J Bone Joint Surg Am* 2006;88(4):744–752
- 36 Berner A, Pfaller C, Dienstknecht T, et al. Arthroplasty of the lunate using bone marrow mesenchymal stromal cells. *Int Orthop* 2011;35(3):379–387
- 37 Shigematsu K, Hattori K, Kobata Y, Kawamura K, Yajima H, Takakura Y. Treatment of Kienböck’s disease with cultured stem cell-seeded hybrid tendon roll interposition arthroplasty: experimental study. *J Orthop Sci* 2006;11(2):198–203
- 38 Ogawa T, Ishii T, Mishima H, et al. Effectiveness of bone marrow transplantation for revitalizing a severely necrotic small bone: experimental rabbit model. *J Orthop Sci* 2010;15(3):381–388
- 39 Ikeguchi R, Kakinoki R, Aoyama T, et al. Regeneration of osteonecrosis of canine scapho-lunate using bone marrow stromal cells: possible therapeutic approach for Kienböck disease. *Cell Transplant* 2006;15(5):411–422
- 40 Hartung T. Thoughts on limitations of animal models. *Parkinsonism Relat Disord* 2008;14(Suppl 2):S81–S83